{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:35:08Z","timestamp":1794897308675,"version":"4.9.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014081","name":"Center for Craft, Creativity and Design","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010638","name":"Huntsman Cancer Institute, University of Utah","doi-asserted-by":"publisher","award":["P30 CS042014"],"award-info":[{"award-number":["P30 CS042014"]}],"id":[{"id":"10.13039\/100010638","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.biomaterials.2025.123464","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T02:48:14Z","timestamp":1749005294000},"page":"123464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["CD38-targeted antibody-polymer drug conjugates for enhanced treatment of multiple myeloma"],"prefix":"10.1016","volume":"324","author":[{"given":"Jiahui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5003-7053","authenticated-orcid":false,"given":"Hasan","family":"Al Faruque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jind\u0159ich","family":"Kope\u010dek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-2698","authenticated-orcid":false,"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3948-8448","authenticated-orcid":false,"given":"Jiyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biomaterials.2025.123464_bib1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.biomaterials.2025.123464_bib2","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/blood-2014-11-568923","article-title":"Treatment options for relapsed and refractory multiple myeloma","volume":"125","author":"Nooka","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2025.123464_bib3","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.3390\/cancers14174082","article-title":"Multiple myeloma therapy: emerging trends and challenges","volume":"14","author":"Dima","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biomaterials.2025.123464_bib4","doi-asserted-by":"crossref","first-page":"20332","DOI":"10.1002\/cam4.6619","article-title":"Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma","volume":"12","author":"Bisht","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.biomaterials.2025.123464_bib5","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/ejh.13046","article-title":"Daratumumab resistance is frequent in advanced-stage multiple myeloma irrespective of CD38 expression and is related to dismal prognosis","volume":"100","author":"Pick","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.biomaterials.2025.123464_bib6","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3390\/jcm9041195","article-title":"Resistance mechanisms towards CD38-directed antibody therapy in multiple myeloma","volume":"9","author":"Franssen","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biomaterials.2025.123464_bib7","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1182\/bloodadvances.2023011295","article-title":"Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma","volume":"7","author":"Portuguese","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.biomaterials.2025.123464_bib8","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3390\/cancers13071571","article-title":"Monoclonal antibodies and antibody drug conjugates in multiple myeloma","volume":"13","author":"Radocha","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biomaterials.2025.123464_bib9","first-page":"1607","article-title":"Belantamab Mafodotin: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs (Basel)"},{"key":"10.1016\/j.biomaterials.2025.123464_bib10","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.biomaterials.2025.123464_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bjh.18298","article-title":"Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma","volume":"199","author":"Abeykoon","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biomaterials.2025.123464_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.678634","article-title":"Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma","volume":"11","author":"Wahab","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biomaterials.2025.123464_bib13","series-title":"Blenrep (Belantamab Mafodotin) Combinations Approved by UK MHRA in relapsed\/refractory Multiple Myeloma","year":"2025"},{"key":"10.1016\/j.biomaterials.2025.123464_bib14","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/cpt.2409","article-title":"Exposure-response analyses for therapeutic dose selection of belantamab mafodotin in patients with relapsed\/refractory multiple myeloma","volume":"110","author":"Ferron-Brady","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biomaterials.2025.123464_bib15","doi-asserted-by":"crossref","first-page":"E451","DOI":"10.1002\/ajh.26728","article-title":"Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience","volume":"97","author":"Mohan","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.biomaterials.2025.123464_bib16","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.18632\/oncotarget.28074","article-title":"Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma","volume":"12","author":"Cho","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.biomaterials.2025.123464_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202007787","article-title":"Daratumumab immunopolymersome-enabled safe and CD38-Targeted chemotherapy and depletion of multiple myeloma","volume":"33","author":"Yu","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biomaterials.2025.123464_bib18","series-title":"Antibody-Polymer-Drug Conjugates. US patent 11, 801,307 B2","author":"Yang","year":"2023"},{"key":"10.1016\/j.biomaterials.2025.123464_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejps.2017.02.034","article-title":"A new construct of antibody-drug conjugates for treatment of B-cell non-hodgkin's lymphomas","volume":"103","author":"Zhang","year":"2017","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.biomaterials.2025.123464_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113682","article-title":"PD-L1 targeted antibody-polymer-epirubicin conjugate prolongs survival in a preclinical murine model of advanced ovarian cancer","volume":"382","author":"Li","year":"2025","journal-title":"J. Control. Release."},{"issue":"Suppl. 1","key":"10.1016\/j.biomaterials.2025.123464_bib21","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2023-186661","article-title":"Development of next generation antibody-polymer-drug conjugates for treatment of multiple myeloma","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2025.123464_bib22","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1021\/acs.biomac.3c00385","article-title":"Antibody polymer conjugates (APCs) for active targeted therapeutic delivery","volume":"24","author":"Kanjilal","year":"2023","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.biomaterials.2025.123464_bib23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jconrel.2020.08.042","article-title":"Overcoming resistance to rituximab in relapsed Non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab","volume":"328","author":"Lidick\u00fd","year":"2020","journal-title":"J. Control. Release."},{"key":"10.1016\/j.biomaterials.2025.123464_bib24","doi-asserted-by":"crossref","first-page":"40508","DOI":"10.1021\/acsomega.3c05206","article-title":"Reinvestigation of the automated synthesis of stoichiometrically conjugated antibodies to access high molecular weight payloads and multiplexed conjugation via an in-solution trans-tagging process","volume":"8","author":"Lehot","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.biomaterials.2025.123464_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00262-006-0168-0","article-title":"Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumor immunity in mice","volume":"56","author":"\u0160\u00edrov\u00e1","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biomaterials.2025.123464_bib26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<108::AID-IJC17>3.0.CO;2-8","article-title":"Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma","volume":"86","author":"Minko","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biomaterials.2025.123464_bib27","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1021\/ma0018087","article-title":"Water-soluble polymers. 81. Direct synthesis of hydrophilic styrenic-based homopolymers and block copolymers in aqueous solution via RAFT","volume":"34","author":"Mitsukami","year":"2001","journal-title":"Macromolecules"},{"key":"10.1016\/j.biomaterials.2025.123464_bib28","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2016.06.004","article-title":"Indium-based and iodine-based labeling of HPMA copolymer-epirubicin conjugates: impact of structure on the in vivo fate","volume":"235","author":"Zhang","year":"2016","journal-title":"J. Control. Release."},{"key":"10.1016\/j.biomaterials.2025.123464_bib29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jconrel.2015.09.045","article-title":"FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy","volume":"218","author":"Yang","year":"2015","journal-title":"J. Control. Release."},{"key":"10.1016\/j.biomaterials.2025.123464_bib30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.addr.2020.07.020","article-title":"Polymer nanomedicines","volume":"156","author":"Kope\u010dek","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biomaterials.2025.123464_bib31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cocis.2017.07.003","article-title":"The light at the end of the tunnel\u2014second generation HPMA conjugates for cancer treatment","volume":"31","author":"Yang","year":"2017","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"10.1016\/j.biomaterials.2025.123464_bib32","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1002\/macp.1983.021841006","article-title":"Polymers containing enzymatically degradable bonds, 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B","volume":"184","author":"Rejmanov\u00e1","year":"1983","journal-title":"Makromol. Chem."},{"key":"10.1016\/j.biomaterials.2025.123464_bib33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0168-3659(88)90039-9","article-title":"Cleavage of oligopeptide side-chains in N-(2-hydroxypropyl)methacrylamide copolymers by mixtures of lysosomal enzymes","volume":"8","author":"\u0160ubr","year":"1988","journal-title":"J. Control. Release."},{"key":"10.1016\/j.biomaterials.2025.123464_bib34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0142-9612(85)90037-7","article-title":"Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers","volume":"6","author":"Rejmanov\u00e1","year":"1985","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2025.123464_bib35","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1182\/blood-2017-03-770776","article-title":"Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab","volume":"129","author":"Garc\u00eda-Guerrero","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2025.123464_bib36","first-page":"695","article-title":"Panobinostat: first global approval","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs (Basel)"},{"key":"10.1016\/j.biomaterials.2025.123464_bib37","series-title":"FDA Approval for Panobinostat in Multiple Myeloma Withdrawn in the United States","year":"2021"},{"key":"10.1016\/j.biomaterials.2025.123464_bib38","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/cells10010130","article-title":"Calreticulin-multifunctional chaperone in immunogenic cell death: potential significance as a prognostic biomarker in ovarian cancer patients","volume":"10","author":"Kielbik","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.biomaterials.2025.123464_bib39","article-title":"Inhibition of immunosuppressive tumors by polymer-assisted inductions of immunogenic cell death and multivalent PD-L1 crosslinking","volume":"30","author":"Li","year":"2020","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.biomaterials.2025.123464_bib40","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jconrel.2021.02.011","article-title":"Combination treatment with immunogenic and anti-PD-L1 polymer-drug conjugates of advanced tumors in a transgenic MMTV-PyMT mouse model of breast cancer","volume":"332","author":"Li","year":"2021","journal-title":"J. Control. Release."},{"key":"10.1016\/j.biomaterials.2025.123464_bib41","doi-asserted-by":"crossref","first-page":"eadd7900","DOI":"10.1126\/scitranslmed.add7900","article-title":"Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity","volume":"15","author":"Vander Mause","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biomaterials.2025.123464_bib42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biomaterials.2025.123464_bib43","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2025.123464_bib44","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3389\/fimmu.2020.01771","article-title":"Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells","volume":"11","author":"Zhu","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biomaterials.2025.123464_bib45","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1158\/1078-0432.CCR-17-3117","article-title":"Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex vivo-expanded autologous NK cells","volume":"24","author":"Wang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2025.123464_bib46","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood.2020006200","article-title":"CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity","volume":"136","author":"Naeimi Kararoudi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2025.123464_bib47","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6630295","article-title":"CD38 and regulation of the immune response cells in cancer","volume":"2021","author":"Dwivedi","year":"2021","journal-title":"J. Oncol."},{"key":"10.1016\/j.biomaterials.2025.123464_bib48","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2025.123464_bib49","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0301-472X(03)00023-7","article-title":"Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells","volume":"31","author":"Greenstein","year":"2003","journal-title":"Exp. Hematol."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961225003837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961225003837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:35:03Z","timestamp":1778765703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961225003837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"alternative-id":["S0142961225003837"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123464","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD38-targeted antibody-polymer drug conjugates for enhanced treatment of multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123464","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"123464"}}